MEDIPEAU Inc Showcases “BARRICURE” Medical Device Brand for Damaged Skin at Malaysia’s ‘Immunodermatology Updates 2025’ Symposium

News provided by

medipeau

Jun. 27, 2025 10:20

공유
스크랩
인쇄
글자크기
Font Size
- ASmall
- AMedium
- ALarge
- AVery Large

CHUNCHEON--(Korea Newswire)--On June 23, 2025, the ‘Immunodermatology Updates 2025’ symposium was held in Malaysia. At this event, CHAYA AND LIGHT SDN. BHD., the official Malaysian distribution partner of MEDIPEAU Inc., introduced the medical device brand “BARRICURE.” The company showcased key products specifically designed for damaged skin. Hosted by the Department of Dermatology at Hospital Selayang under Malaysia’s Ministry of Health, the symposium brought together dermatologists and healthcare professionals from across Malaysia to share the latest trends and clinical insights in immunodermatology.

CHAYA AND LIGHT SDN. BHD. focused on promoting BARRICURE Lotion MD to local medical professionals. This product is specifically formulated for a wide range of skin conditions, including first-degree burns, severe dryness, barrier damage, and pruritic (itchy) skin. It forms a physical protective layer on the skin, delivering exceptional moisturizing effects. The lotion incorporates MEDIPEAU’s patented formulation technology, MDmellar®, which supports lipid balance and barrier restoration. It also contains DERMA-CLERA®, a naturally derived patented ingredient known to help relieve dermatitis and itching.

Healthcare professionals attending the symposium showed strong interest in BARRICURE Lotion MD, particularly in its efficacy for skin barrier recovery and clinical applicability. Many expressed positive feedback after testing the product at the booth.

An official from CHAYA AND LIGHT SDN. BHD. said that this symposium has provided a valuable opportunity to engage directly with dermatologists and medical device buyers in Malaysia, allowing for highlighting the strengths of products. The official also expressed expectations to strengthen the distribution network in Malaysian hospitals and clinics and further expand BARRICURE’s presence in the local market through close collaboration with MEDIPEAU Inc.

Meanwhile, BARRICURE is CE certified for export to Europe and is currently being actively exported to various countries, including Singapore and Malaysia in Asia, as well as the United States and the Middle East. MEDIPEAU Inc. plans to further expand its overseas exports in the future.

About MEDIPEAU

MEDIPEAU is a biotechnology company dedicated to the reconstruction of healthy skin through natural compound chemistry and cutting-edge biotechnologies. The company operates a “Pruritus Research Institute,” specializing in the study of skin diseases accompanied by itching, such as atopic dermatitis, psoriasis, burns, and scars. Committed to outstanding research and development, MEDIPEAU ensures consistent product quality by manufacturing and managing its products in facilities certified for Good Manufacturing Practice (GMP) for medical devices.

Website: http://medipeau.co.kr